Advanced Filters
noise
Found 842 clinical trials

Health Behavior Change in Midlife Adults at Risk for Alzheimer's Disease

Modifying health behaviors like physical activity level, diet, stress, and mental activity level can lower risk for Alzheimer's disease, but many middle-aged and older adults find it difficult to sustain health behavior changes over the long term. This project will develop a new intervention that educates people about Alzheimer's disease …

45 - 69 years of age All Phase N/A
W Willem de Haan, PhD

Transcranial Magnetic Stimulation to Slow Down Cognitive Decline in Alzheimer's Disease

New amyloid-targeting drugs for Alzheimer's disease (AD) offer minimal or unclear efficacy and often cause adverse events, highlighting the need for new therapies. In recent years, repetitive transcranial magnetic stimulation (rTMS) has shown increasing success. A recent randomized, double-blind, sham-controlled, phase 2 demonstrated promising results from a 24-week rTMS treatment …

50 - 85 years of age All Phase N/A

A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

The purpose is to evaluate the biomarker effect, safety, and tolerability of investigational study drugs in participants who are known to have an Alzheimer's disease (AD)-causing mutation. Stage 1 will determine if treatment with the study drug prevents or slows the rate of amyloid beta (Aβ) pathological disease accumulation demonstrated …

18 years of age All Phase 2/3
R Rachel Ruiz

Testing the Effects of a Text Message Caregiver Support Intervention for Latinos

The goal of this randomized clinical trial it to test the efficacy of CuidaTEXT, the first Alzheimer's disease and Related Dementias (ADRD) caregiver support intervention to capitalize on text messaging, among Latinos. Researchers will compare those who receive the CuidaTEXT intervention to those who do not receive the intervention to …

18 - 100 years of age All Phase N/A
L Linda Wirta

A Study of AMDX-2011P in Participants With Alzheimer's Disease

The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with Alzheimer's Disease (AD).

18 years of age All Phase 2
R Rujin Wang

Alzheimer's Disease Treated With Vagus Nerve Stimulation

The goal of this clinical trial is to evaluate the safety and efficacy of vagus nerve stimulation (VNS) for treating Alzheimer's disease (AD) in patients aged 50-80 years with mild cognitive impairment to moderate Alzheimer's disease. The main questions it aims to answer are: Is the change from baseline in …

50 - 80 years of age All Phase N/A
F Francesca Pistoia, MD

Transcranial Pulse Stimulation. a Potential Treatment for Early Dementia

Alzheimer's Disease (AD) is characterized by the absence of treatments to slow, stop, or reverse its course, with patients finally losing cognitive functions, skills and independence. It is a chronic degenerative disease with high social and medical burden worldwide: AD ranked third among neurological disorders in terms of disability-adjusted life …

18 years of age All Phase N/A
D Dag Aarsland, PhD

Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD)

The goal of this placebo-controlled double-blind Phase 2 clinical trial is to test in people with early Alzheimer's Disease. The main questions it aims to answer are: Does treatment with fasudil, a ROCK-inhibitor, lead to significant improvement in working memory (based on computer-based working memory composite scores) compared to placebo …

50 - 100 years of age All Phase 2
J Jianping Jia, MD,PhD

The Ketogenic Diet in the Treatment of Alzheimer's Disease

This research is a randomized, double-blind, placebo-parallel controlled, and multi-center clinical study in China, aiming to evaluate the tolerability, efficacy, and safety of JT821 (Ketogenic Diet) in the treatment of mild to moderate Alzheimer's disease. The ketogenic diet (KD) is a low-carbohydrate, adequate protein and high-fat diet. KD was shown …

50 - 85 years of age All Phase N/A
J Joe Mwanza

A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK

This study will assess if drug (NIO752) reduces production of a protein, tau, by the brain. Normally tau maintains the internal skeleton of nerve cells. In Alzheimer's disease (AD) it builds up in the brain, causing damage. Abnormal tau proteins cling to each other forming 'tangles' inside nerve cells, which …

21 - 80 years of age All Phase 1

Simplify language using AI